Literature DB >> 2712199

Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.

S C Kliks1, A Nisalak, W E Brandt, L Wahl, D S Burke.   

Abstract

Serum specimens collected during a prospective study of dengue infections among schoolchildren in Bangkok were tested for their ability to enhance dengue 2 (DEN-2) virus growth in human monocytes in vitro. Two groups of dengue-immune sera were compared: 32 dengue antibody positive serum specimens from children who subsequently developed asymptomatic secondary dengue infections; and 9 dengue antibody positive serum specimens from children who subsequently developed severe symptomatic secondary dengue infections, 8 of which were clinically diagnosed as dengue hemorrhagic fever. Antibody-dependent enhancement of virus growth was quantitated by measurement of virus yields in supernatant fluids of normal human monocyte cultures that were infected with DEN-2 virus in the presence of undiluted test serum. Only 4 of 32 (12%) preinfection sera from asymptomatic children, but 6 of 9 (67%) preinfection sera from symptomatic children, had significant enhancing activity (P less than 0.001). High serum DEN-2 antibody dependent enhancing activity is a significant (relative risk = 6.2) risk factor for severe illness among children in a dengue hemorrhagic fever endemic region. Dengue antibodies can be neutralizing and therefore protective, or they can be enhancing and increase the risk of dengue hemorrhagic fever.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2712199     DOI: 10.4269/ajtmh.1989.40.444

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  201 in total

1.  Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.

Authors:  R G van Der Most; K Murali-Krishna; R Ahmed; J H Strauss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Infection of human cells by dengue virus is modulated by different cell types and viral strains.

Authors:  M S Diamond; D Edgil; T G Roberts; B Lu; E Harris
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

Authors:  Vanda Akico Ueda Fick de Souza; Silvana Fernandes; Evaldo Stanislau Araújo; Adriana Fumie Tateno; Olímpia M N P F Oliveira; Renato Reis Oliveira; Cláudio Sérgio Pannuti
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

5.  Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

Authors:  P R Johnson; D C Montefiori; S Goldstein; T E Hamm; J Zhou; S Kitov; N L Haigwood; L Misher; W T London; J L Gerin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

7.  Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation.

Authors:  M Juffrie; G M van Der Meer; C E Hack; K Haasnoot; A J Veerman; L G Thijs
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

8.  Dynamic effects of antibody-dependent enhancement on the fitness of viruses.

Authors:  Derek A T Cummings; Ira B Schwartz; Lora Billings; Leah B Shaw; Donald S Burke
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

9.  Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever.

Authors:  Anna P Durbin; Maria José Vargas; Kimberli Wanionek; Samantha N Hammond; Aubree Gordon; Crisanta Rocha; Angel Balmaseda; Eva Harris
Journal:  Virology       Date:  2008-05-02       Impact factor: 3.616

10.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.